Relapsing polychondritis: An autoimmune disease with many faces

Abstract Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autoimmunity reviews 2010-06, Vol.9 (8), p.540-546
Hauptverfasser: Lahmer, Tobias, Treiber, Matthias, von Werder, Alexander, Foerger, Frauke, Knopf, Andreas, Heemann, Uwe, Thuermel, Klaus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 546
container_issue 8
container_start_page 540
container_title Autoimmunity reviews
container_volume 9
creator Lahmer, Tobias
Treiber, Matthias
von Werder, Alexander
Foerger, Frauke
Knopf, Andreas
Heemann, Uwe
Thuermel, Klaus
description Abstract Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with other diseases especially systemic vasculitis or myelodysplatic syndrome can be detected. The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of therapy strategies. Often the medication in current use is largely empiric and based on case reports. Therefore different immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil and also new approaches like tumor necrosis factor alpha blockers (TNF-alpha antagonists) have been used for the treatment of severe manifestations of RPC with varying degrees of efficacy. This review gives a close look to clinical manifestation, diagnosis and also therapy options of RPC.
doi_str_mv 10.1016/j.autrev.2010.02.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754539916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1568997210000388</els_id><sourcerecordid>754539916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-2489380083ce97bf9b5a955c3473073e29620604e5b82a2edec710482f5394e93</originalsourceid><addsrcrecordid>eNqFkUtLAzEUhYMotlb_gcjsXLXmNTOJC6UUXyAIPtYhzdyxqTOZmsxU-u9NbRVxYzYJl-_cc3MuQscEjwgm2dl8pLvWw3JEcSxhOorFHdQnaSaGUuZ099e7hw5CmONISCr3UY9iSlLMRR9dPkKlF8G612TRVCsza1zhbWvDeTJ2SXRobF13DpLCBtABkg_bzpJau1VSagPhEO2VugpwtL0H6OX66nlyO7x_uLmbjO-HhnPRDikXkgmMBTMg82kpp6mWaWoYzxnOGVCZUZxhDulUUE2hAJOTOCAtUyY5SDZAp5u-C9-8dxBaVdtgoKq0g6YLKk95JCXJIsk3pPFNCB5KtfC21n6lCFbr5NRcbZJT6-QUpgp_yU62Bt20huJH9B1VBC42AMRvLi14FYwFZ6CwHkyrisb-5_C3gamss0ZXb7CCMG8672KEiqgQBeppvb318giOhwnBPgF_qJS8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754539916</pqid></control><display><type>article</type><title>Relapsing polychondritis: An autoimmune disease with many faces</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lahmer, Tobias ; Treiber, Matthias ; von Werder, Alexander ; Foerger, Frauke ; Knopf, Andreas ; Heemann, Uwe ; Thuermel, Klaus</creator><creatorcontrib>Lahmer, Tobias ; Treiber, Matthias ; von Werder, Alexander ; Foerger, Frauke ; Knopf, Andreas ; Heemann, Uwe ; Thuermel, Klaus</creatorcontrib><description>Abstract Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with other diseases especially systemic vasculitis or myelodysplatic syndrome can be detected. The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of therapy strategies. Often the medication in current use is largely empiric and based on case reports. Therefore different immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil and also new approaches like tumor necrosis factor alpha blockers (TNF-alpha antagonists) have been used for the treatment of severe manifestations of RPC with varying degrees of efficacy. This review gives a close look to clinical manifestation, diagnosis and also therapy options of RPC.</description><identifier>ISSN: 1568-9972</identifier><identifier>EISSN: 1568-9972</identifier><identifier>EISSN: 1873-0183</identifier><identifier>DOI: 10.1016/j.autrev.2010.02.016</identifier><identifier>PMID: 20215048</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Allergy and Immunology ; Anti-type II collagen antibodies ; Auricular chondritis ; Autoimmune disease ; Cartilage disorder ; Humans ; Immunosuppressive Agents - therapeutic use ; Matrilin-1 ; McAdam's criteria ; Polychondritis, Relapsing ; Relapsing polychondritis ; TNF-alpha antagonists ; TNF-alpha staining ; Vasculitis</subject><ispartof>Autoimmunity reviews, 2010-06, Vol.9 (8), p.540-546</ispartof><rights>Elsevier B.V.</rights><rights>2010 Elsevier B.V.</rights><rights>Copyright 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-2489380083ce97bf9b5a955c3473073e29620604e5b82a2edec710482f5394e93</citedby><cites>FETCH-LOGICAL-c448t-2489380083ce97bf9b5a955c3473073e29620604e5b82a2edec710482f5394e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.autrev.2010.02.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20215048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lahmer, Tobias</creatorcontrib><creatorcontrib>Treiber, Matthias</creatorcontrib><creatorcontrib>von Werder, Alexander</creatorcontrib><creatorcontrib>Foerger, Frauke</creatorcontrib><creatorcontrib>Knopf, Andreas</creatorcontrib><creatorcontrib>Heemann, Uwe</creatorcontrib><creatorcontrib>Thuermel, Klaus</creatorcontrib><title>Relapsing polychondritis: An autoimmune disease with many faces</title><title>Autoimmunity reviews</title><addtitle>Autoimmun Rev</addtitle><description>Abstract Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with other diseases especially systemic vasculitis or myelodysplatic syndrome can be detected. The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of therapy strategies. Often the medication in current use is largely empiric and based on case reports. Therefore different immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil and also new approaches like tumor necrosis factor alpha blockers (TNF-alpha antagonists) have been used for the treatment of severe manifestations of RPC with varying degrees of efficacy. This review gives a close look to clinical manifestation, diagnosis and also therapy options of RPC.</description><subject>Allergy and Immunology</subject><subject>Anti-type II collagen antibodies</subject><subject>Auricular chondritis</subject><subject>Autoimmune disease</subject><subject>Cartilage disorder</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Matrilin-1</subject><subject>McAdam's criteria</subject><subject>Polychondritis, Relapsing</subject><subject>Relapsing polychondritis</subject><subject>TNF-alpha antagonists</subject><subject>TNF-alpha staining</subject><subject>Vasculitis</subject><issn>1568-9972</issn><issn>1568-9972</issn><issn>1873-0183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtLAzEUhYMotlb_gcjsXLXmNTOJC6UUXyAIPtYhzdyxqTOZmsxU-u9NbRVxYzYJl-_cc3MuQscEjwgm2dl8pLvWw3JEcSxhOorFHdQnaSaGUuZ099e7hw5CmONISCr3UY9iSlLMRR9dPkKlF8G612TRVCsza1zhbWvDeTJ2SXRobF13DpLCBtABkg_bzpJau1VSagPhEO2VugpwtL0H6OX66nlyO7x_uLmbjO-HhnPRDikXkgmMBTMg82kpp6mWaWoYzxnOGVCZUZxhDulUUE2hAJOTOCAtUyY5SDZAp5u-C9-8dxBaVdtgoKq0g6YLKk95JCXJIsk3pPFNCB5KtfC21n6lCFbr5NRcbZJT6-QUpgp_yU62Bt20huJH9B1VBC42AMRvLi14FYwFZ6CwHkyrisb-5_C3gamss0ZXb7CCMG8672KEiqgQBeppvb318giOhwnBPgF_qJS8</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Lahmer, Tobias</creator><creator>Treiber, Matthias</creator><creator>von Werder, Alexander</creator><creator>Foerger, Frauke</creator><creator>Knopf, Andreas</creator><creator>Heemann, Uwe</creator><creator>Thuermel, Klaus</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20100601</creationdate><title>Relapsing polychondritis: An autoimmune disease with many faces</title><author>Lahmer, Tobias ; Treiber, Matthias ; von Werder, Alexander ; Foerger, Frauke ; Knopf, Andreas ; Heemann, Uwe ; Thuermel, Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-2489380083ce97bf9b5a955c3473073e29620604e5b82a2edec710482f5394e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Allergy and Immunology</topic><topic>Anti-type II collagen antibodies</topic><topic>Auricular chondritis</topic><topic>Autoimmune disease</topic><topic>Cartilage disorder</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Matrilin-1</topic><topic>McAdam's criteria</topic><topic>Polychondritis, Relapsing</topic><topic>Relapsing polychondritis</topic><topic>TNF-alpha antagonists</topic><topic>TNF-alpha staining</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lahmer, Tobias</creatorcontrib><creatorcontrib>Treiber, Matthias</creatorcontrib><creatorcontrib>von Werder, Alexander</creatorcontrib><creatorcontrib>Foerger, Frauke</creatorcontrib><creatorcontrib>Knopf, Andreas</creatorcontrib><creatorcontrib>Heemann, Uwe</creatorcontrib><creatorcontrib>Thuermel, Klaus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Autoimmunity reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lahmer, Tobias</au><au>Treiber, Matthias</au><au>von Werder, Alexander</au><au>Foerger, Frauke</au><au>Knopf, Andreas</au><au>Heemann, Uwe</au><au>Thuermel, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapsing polychondritis: An autoimmune disease with many faces</atitle><jtitle>Autoimmunity reviews</jtitle><addtitle>Autoimmun Rev</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>9</volume><issue>8</issue><spage>540</spage><epage>546</epage><pages>540-546</pages><issn>1568-9972</issn><eissn>1568-9972</eissn><eissn>1873-0183</eissn><abstract>Abstract Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with other diseases especially systemic vasculitis or myelodysplatic syndrome can be detected. The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of therapy strategies. Often the medication in current use is largely empiric and based on case reports. Therefore different immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil and also new approaches like tumor necrosis factor alpha blockers (TNF-alpha antagonists) have been used for the treatment of severe manifestations of RPC with varying degrees of efficacy. This review gives a close look to clinical manifestation, diagnosis and also therapy options of RPC.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>20215048</pmid><doi>10.1016/j.autrev.2010.02.016</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1568-9972
ispartof Autoimmunity reviews, 2010-06, Vol.9 (8), p.540-546
issn 1568-9972
1568-9972
1873-0183
language eng
recordid cdi_proquest_miscellaneous_754539916
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Allergy and Immunology
Anti-type II collagen antibodies
Auricular chondritis
Autoimmune disease
Cartilage disorder
Humans
Immunosuppressive Agents - therapeutic use
Matrilin-1
McAdam's criteria
Polychondritis, Relapsing
Relapsing polychondritis
TNF-alpha antagonists
TNF-alpha staining
Vasculitis
title Relapsing polychondritis: An autoimmune disease with many faces
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T20%3A07%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapsing%20polychondritis:%20An%20autoimmune%20disease%20with%20many%20faces&rft.jtitle=Autoimmunity%20reviews&rft.au=Lahmer,%20Tobias&rft.date=2010-06-01&rft.volume=9&rft.issue=8&rft.spage=540&rft.epage=546&rft.pages=540-546&rft.issn=1568-9972&rft.eissn=1568-9972&rft_id=info:doi/10.1016/j.autrev.2010.02.016&rft_dat=%3Cproquest_cross%3E754539916%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=754539916&rft_id=info:pmid/20215048&rft_els_id=S1568997210000388&rfr_iscdi=true